Saxenda continues to dominate the market and now commands 50.4%, up 0.6 pp w/w, based on value market share, or 14.3%, up 0.8 pp w/w, based on volume market share. Among the basal insulins, Tresiba gr
-
Saxenda continues to dominate the market and now commands 50.4%, up 0.6 pp w/w, based on value market share, or 14.3%, up 0.8 pp w/w, based on volume market share. Among the basal insulins, Tresiba grew 4.5% w/w to reach 16,941 weekly prescriptions, while Levemir, up 0.8%, lagged behind the overall US basal insulin market, growing 1.5% w/w. Novo's combined TRx market share was down 0.1 pp w/w to 25.8%, with Tresiba
capturing 3.4% (NRx4.4%), up 0.1 pp w/w.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind